Please login to the form below

Not currently logged in

Deal Watch table for June 2013

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during June 2013.

For an indepth analysis of these deals, read 'Pharma deals during June 2013'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

Pfizer (Wyeth) + Takeda / Teva +  Sun Pharmaceutical

Patent settlement

Infringement of Protonix patent 2,150
Pearl Therapeutics / AstraZeneca


Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III) 1,150
Conceptus / Bayer Acquisition Bayer acquires >90 per cent shares includes the product Essure, for non-surgical permanent birth control (marketed) 1,100
Merck / Aspen Acquisition Aspen acquires Merck drugs/ manufacturing business 1,000
Aragon Pharmaceuticals / J&J Acquisition Includes ARN 509 (second generation  androgen receptor signalling inhibitor) for castration-resistant prostate cancer (phase II) 1,000
MorphoSys  / Celgene

Strategic collaboration

Joint development and co-promotion of MOR 202 in multiple myeloma (phase I/II) 818
CytomX / Pfizer Collaboration and exclusive licence to selected PDCs Collaboration for Probody Drug conjugates (PDCs) in oncology (platform) 635
MorphoSys / GSK Licence to develop and commercialise MOR 103 (HuCA-derived MAb against GM-CSF), for mild to moderate RA (phase I/II) 580
Seattle Genetics / Bayer HealthCare Collaboration for development and commmercialisation Auristatin based antibody-drug conjugate (ADC) technology for certain oncology targets (platform)  520
Cytokinetics / Astellas Exclusive licence to develop and commercialise Collaboration for therapies associated with muscle weakness and rights to CK 2127107 (phase I) for certain indications; 490
Immunocore / Genentech Research collaboration and licence Discovery and development of multiple targets using Immunocore's ImmTAC technology (platform)  320+
Medicines360 / Actavis* Licence US commercial rights to LNG20 Intrauterine Device (IUD) (phase III) 175
MicroDose Therapeutx / Teva Acquisition Acquisition of inhalation technology including MDT-637 for RSV (phase II) 165
Novartis / Questcor* Development rights Rights to develop Synacthen (tetracosactide,   melanocortin receptor agonist) and Synacthen Depot (approved in Europe for autoimmune & inflammatory conditions) 135
Fera / Perrigo Product portfolio acquisition Ophthalmic sterile ointment and solution product portfolio 129
Cytokinetics / Amgen** Extension of existing licence to Japan Small molecules to activate heart muscle, including omecamtiv mecarbil (phase II) 75
Taiwan Liposome Company / SciClone Pharmaceuticals*** Exclusive licence Commercialisation of ProFlow (lipid emulsion-based formulation of alprostadil) for peripheral arterial disease (approved Taiwan) 39.5
BioLineRx / Jiangsu Chia-tai Tianqing Pharmaceutical (CTTQ)† Collaboration and licence BL8030, second generation protease inhibitor in development for Hepatitis C (preclinical)


Isconova / Novavax Acquisition Proprietary vaccine adjuvant technology 30

Unless noted, transactions are for global rights
* US only
** Japan only
*** China, Hong Kong and Macau
† China and Hong Kong

The Deal Watch table is compiled by Medius Associates

12th July 2013

The Deal Watch table is compiled by Medius Associates

12th July 2013

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Welcome to HAVAS LYNX, a leading global healthcare communications group....